Home Chinese Virus Ivermectin Works

Ivermectin Works

Author

Date

Category

Study Shows Ivermectin Has ‘Significant Impact’ On COVID19

From the American Journal of Therapeutics

A Cochrane-standard (=highest) review and meta-analysis of Ivermectin against Covid-19 by Bryant-Lawrie, now peer-reviewed and published, concludes that the evidence justifies the global adoption of this re-purposed, cheap medicine.

Background:

Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.

Areas Of Uncertainty:

We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.

Data Sources:

We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion.

Therapeutic Advances:

Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis.

This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method.

Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence.

Low-certainty evidence suggested that there may be no benefit with ivermectin for “need for mechanical ventilation,” whereas effect estimates for “improvement” and “deterioration” clearly favored ivermectin use.

Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty.

Conclusions:

Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Previous articleFollow The Money
Next articleHave Your Say

1 COMMENT

Recent posts

The Killer in the Bloodstream: the “Spike Protein”

The Killer in the Bloodstream: the “Spike Protein” Has there ever been a greater threat to humanity than the Covid vaccine? By Mike Whitney Global Research, July 31,...

How True

For the first time in human history, we can transmit a disease we don’t have…. to those who are immunized against it. Sharri Markson, Liam...

Stealing High-paid Jobs

How white Aussies who pretend to be Aboriginal are taking over universities and stealing high-paid jobs meant for real Indigenous Australians. By Stephen Gibbs. Aboriginal academic Victoria...

Recent comments

Braybots nemesis on Have Your Say
B Venton on How True
bells on Have Your Say
PhilP on Have Your Say
Editor on Have Your Say
Alice on Have Your Say
PhilP on Have Your Say
PhilP on Have Your Say

The way we all feel about this useless government

Hamilton
overcast clouds
14.1 ° C
15 °
13.4 °
71 %
5.4kmh
93 %
Tue
13 °
Wed
12 °
Thu
14 °
Fri
13 °
Sat
14 °
NZD - New Zealand Dollar
USD
1.4295
EUR
1.6971
AUD
1.0534
CAD
1.1421
GBP
1.9859
JPY
0.0131
CNY
0.2211
INR
0.0192